Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 59

The HSCT activity continues to increase in developing countries which constitute majority of the low‐ and middle‐income countries [39]. The recent uptrend in donor availability for haploidentical HSCT has been instrumental in increasing numbers of allogeneic HSCT in these areas [40]. The trends in allogeneic HSCT increase are found in both Asia and Africa, though there is wide variation in the HSCT practices among countries. Allogeneic and autologous HSCT survivors face challenges in long‐term follow‐up and survivorship care that are unique in resource‐limited countries. Herein, we describe the essential need of LTFU clinic for recipients of HSCT in resource‐limited countries and also touch upon current challenges and potential solutions.